These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26316565)

  • 1. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
    Wang YY; Wang K; Li SW; Wang JF; Ma J; Jiang T; Dai JP
    AJNR Am J Neuroradiol; 2015 Nov; 36(11):2023-9. PubMed ID: 26316565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
    Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T
    Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H; Vallières M; Bai HX; Su C; Tang H; Oldridge D; Zhang Z; Xiao B; Liao W; Tao Y; Zhou J; Zhang P; Yang L
    Neuro Oncol; 2017 Jun; 19(6):862-870. PubMed ID: 28339588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
    Gozé C; Blonski M; Le Maistre G; Bauchet L; Dezamis E; Page P; Varlet P; Capelle L; Devaux B; Taillandier L; Duffau H; Pallud J
    Neuro Oncol; 2014 Aug; 16(8):1100-9. PubMed ID: 24847087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
    Kim D; Kim S; Kim SH; Chang JH; Yun M
    Clin Nucl Med; 2018 May; 43(5):311-316. PubMed ID: 29485450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the association between contrast enhancement pattern, surgical resection, and prognosis in anaplastic glioma patients.
    Wang Y; Wang K; Wang J; Li S; Ma J; Dai J; Jiang T
    Neuroradiology; 2016 Apr; 58(4):367-74. PubMed ID: 26795126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of
    Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
    Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
    PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.
    Darvishi P; Batchala PP; Patrie JT; Poisson LM; Lopes MB; Jain R; Fadul CE; Schiff D; Patel SH
    AJNR Am J Neuroradiol; 2020 May; 41(5):815-821. PubMed ID: 32327434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
    Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
    Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
    Suchorska B; Schüller U; Biczok A; Lenski M; Albert NL; Giese A; Kreth FW; Ertl-Wagner B; Tonn JC; Ingrisch M
    Eur J Cancer; 2019 Jan; 107():15-27. PubMed ID: 30529899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MR Elastography Analysis of Glioma Stiffness and
    Pepin KM; McGee KP; Arani A; Lake DS; Glaser KJ; Manduca A; Parney IF; Ehman RL; Huston J
    AJNR Am J Neuroradiol; 2018 Jan; 39(1):31-36. PubMed ID: 29074637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas.
    Niu L; Feng WH; Duan CF; Liu YC; Liu JH; Liu XJ
    Biomed Res Int; 2020; 2020():4630218. PubMed ID: 33163535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
    Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
    Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.